Emmaus Life Sciences (NASDAQ:EMMA) Director Wei Peu Zen bought 12,545 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were bought at an average price of $4.20 per share, for a total transaction of $52,689.00.
Wei Peu Zen also recently made the following trade(s):
- On Monday, September 9th, Wei Peu Zen bought 40,000 shares of Emmaus Life Sciences stock. The shares were bought at an average price of $4.25 per share, for a total transaction of $170,000.00.
- On Friday, August 30th, Wei Peu Zen acquired 3,400 shares of Emmaus Life Sciences stock. The stock was acquired at an average price of $3.30 per share, for a total transaction of $11,220.00.
- On Wednesday, August 28th, Wei Peu Zen acquired 2,345 shares of Emmaus Life Sciences stock. The stock was acquired at an average price of $2.80 per share, for a total transaction of $6,566.00.
NASDAQ:EMMA opened at $2.77 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market capitalization of $131.48 million, a price-to-earnings ratio of -0.25 and a beta of 2.91. Emmaus Life Sciences has a 12-month low of $2.49 and a 12-month high of $14.70.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.